HUP0102300A2 - Diazepinszármazékok alkalmazása szomatosztatin-receptor által befolyásolt betegségek kezelésére szánt gyógyszerek előállítására, valamint új vegyületek - Google Patents

Diazepinszármazékok alkalmazása szomatosztatin-receptor által befolyásolt betegségek kezelésére szánt gyógyszerek előállítására, valamint új vegyületek

Info

Publication number
HUP0102300A2
HUP0102300A2 HU0102300A HUP0102300A HUP0102300A2 HU P0102300 A2 HUP0102300 A2 HU P0102300A2 HU 0102300 A HU0102300 A HU 0102300A HU P0102300 A HUP0102300 A HU P0102300A HU P0102300 A2 HUP0102300 A2 HU P0102300A2
Authority
HU
Hungary
Prior art keywords
group
general formula
treating diseases
new compounds
hydrogen atom
Prior art date
Application number
HU0102300A
Other languages
English (en)
Inventor
Dennis Bigg
Anne-Marie Liberatore
Jacques Pommier
John Taylor
Original Assignee
Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) filed Critical Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)
Publication of HUP0102300A2 publication Critical patent/HUP0102300A2/hu
Publication of HUP0102300A3 publication Critical patent/HUP0102300A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

A találmány az (I) általános képletű vegyületek - ahol aszubsztituensek fő jelentése a következők: W jelentése hidrogénatomvagy R-X-C(Y) általános képletű csoport, amelyben R jelentésearilcsoport vagy heteroarilcsoport, X jelentése -(CH2)n-Z általánosképletű csoport, amelyben Z jelentése kovalens kötés, NH, O, vagy S ésn jelentése 0, 1 vagy 2, Y jelentése 0 vagy S; R1 jelentésehidrogénatom, hidroxilcsoport, halogénatom, rövid szénláncúalkilcsoport vagy rövid szénláncú alkoxicsoport; R2a és R2b jelentéseegymástól függetlenül hidrogénatom, rövid szénláncú alkilcsoport,rövid szénláncú alkenilcsoport vagy rövid szénláncú alkinilcsoport; R3jelentése hidrogénatom, halogénatom, nitrocsoport, cianocsoport vagy1-10 szénatomos alkilcsoport -vagy e vegyületek sóinak azalkalmazására vonatkozik szomatosztatin-receptorok által befolyásoltkóros állapotok vagy betegségek kezelésére alkalmas gyógyszerekelőállításához. A találmány kiterjed új származékokra is. Ó
HU0102300A 1998-06-15 1999-06-15 Use of diazepin derivatives for preparing medicines for treating diseases influenced by somatostatine receptor, and new compounds HUP0102300A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9807509A FR2779652B1 (fr) 1998-06-15 1998-06-15 Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
PCT/FR1999/001422 WO1999065917A1 (fr) 1998-06-15 1999-06-15 Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique

Publications (2)

Publication Number Publication Date
HUP0102300A2 true HUP0102300A2 (hu) 2001-11-28
HUP0102300A3 HUP0102300A3 (en) 2002-10-28

Family

ID=9527389

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102300A HUP0102300A3 (en) 1998-06-15 1999-06-15 Use of diazepin derivatives for preparing medicines for treating diseases influenced by somatostatine receptor, and new compounds

Country Status (19)

Country Link
US (1) US7015213B1 (hu)
EP (1) EP1087978A1 (hu)
JP (1) JP2002518400A (hu)
KR (1) KR20010052836A (hu)
CN (1) CN100348600C (hu)
AR (1) AR019669A1 (hu)
AU (1) AU758206B2 (hu)
CA (1) CA2335724A1 (hu)
FR (1) FR2779652B1 (hu)
HK (1) HK1039780A1 (hu)
HU (1) HUP0102300A3 (hu)
IL (1) IL139954A0 (hu)
MY (1) MY118652A (hu)
NO (1) NO20006352D0 (hu)
NZ (1) NZ509313A (hu)
PL (1) PL344831A1 (hu)
RU (1) RU2229299C2 (hu)
TW (1) TW513434B (hu)
WO (1) WO1999065917A1 (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987105B2 (en) * 2000-04-28 2006-01-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of thienotriazolodiazepines
WO2002057241A1 (en) * 2000-12-22 2002-07-25 Bayer Pharmaceuticals Corporation 8-(AMINOALKOXYMINO)-8H-DIBENZO[a,e]TRIAZOLO[4,5-c]CYCLOHEPTENES AS GROWTH HORMONE SECRETAGOGUES
WO2009084693A1 (ja) * 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
BR122014024883A2 (pt) 2010-05-14 2019-08-20 Dana-Farber Cancer Institute, Inc. Compostos no tratamento de neoplasia
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
WO2013184878A1 (en) 2012-06-06 2013-12-12 Constellation Pharmaceuticals, Inc. Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
WO2015013635A2 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CN106456653A (zh) 2014-02-28 2017-02-22 腾沙治疗公司 高胰岛素血症相关病症的治疗
US9969747B2 (en) 2014-06-20 2018-05-15 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide
CA2955077A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
BR112017002369A2 (pt) 2014-08-08 2017-12-05 Dana Farber Cancer Inst Inc derivados de diazepana e usos dos mesmos
EA033325B1 (ru) 2014-10-27 2019-09-30 Тэнша Терапеутикс, Инк. Ингибиторы бромодомена
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017044792A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazoldiazepines and uses thereof
BR112018004618A2 (pt) 2015-09-11 2018-09-25 Dana-Farber Cancer Institute, Inc. ciano tienotriazoldiazepinas e usos das mesmas
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
TWI707859B (zh) * 2017-09-07 2020-10-21 日商衛材R&D企管股份有限公司 五環化合物
AR118235A1 (es) 2019-03-05 2021-09-22 Eisai R&D Man Co Ltd Heterociclos pentacíclicos
AU2020233452A1 (en) 2019-03-05 2021-09-02 Eisai R&D Management Co., Ltd. Salt of pentacyclic compound and crystals thereof
CN111533745A (zh) * 2020-05-20 2020-08-14 成都药明康德新药开发有限公司 叔丁基-3-(氨基甲基)二氢-5h-三唑并二氮杂卓-8(9h)-甲酸基酯制法
CN117624188A (zh) 2020-11-16 2024-03-01 勃林格殷格翰国际有限公司 作为血小板活化因子受体拮抗剂的环戊烷并噻吩甲酰胺衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95708C (fi) * 1988-10-31 1996-03-11 Eisai Co Ltd Analogiamenetelmä 1,4-diatsepiinijohdannaisen ja sen farmaseuttisesti sopivan suolan valmistamiseksi
GB8907256D0 (en) * 1989-03-31 1989-05-17 Rech Et D Applic Scient Scras New derivatives of hetrazepine as anti-asthmatic anti-allergic and gastro-intestinal protectors
OA09202A (fr) * 1990-04-02 1992-06-30 Sod Conseils Rech Applic Procédé de préparation des nouveaux dérivés de la thiéno-triazolo-diazépine.
DE4107521A1 (de) * 1991-03-08 1992-09-10 Boehringer Ingelheim Kg Neue acylaminosubstituierte hetrazepine
JP3239364B2 (ja) * 1991-10-11 2001-12-17 ウェルファイド株式会社 骨粗鬆症治療薬およびジアゼピン化合物
ZA979701B (en) * 1996-10-31 1998-05-21 Novo Nordisk As Novo Nordisk A Constrained somatostatin agonists and antagonists.Constrained somatostatin agonists and antagonists.

Also Published As

Publication number Publication date
US7015213B1 (en) 2006-03-21
AU4149599A (en) 2000-01-05
WO1999065917A1 (fr) 1999-12-23
NO20006352L (no) 2000-12-13
NZ509313A (en) 2002-11-26
CA2335724A1 (fr) 1999-12-23
CN100348600C (zh) 2007-11-14
HUP0102300A3 (en) 2002-10-28
FR2779652B1 (fr) 2001-06-08
CN1309657A (zh) 2001-08-22
KR20010052836A (ko) 2001-06-25
PL344831A1 (en) 2001-11-19
FR2779652A1 (fr) 1999-12-17
MY118652A (en) 2004-12-31
AU758206B2 (en) 2003-03-20
NO20006352D0 (no) 2000-12-13
IL139954A0 (en) 2002-02-10
HK1039780A1 (zh) 2002-05-10
AR019669A1 (es) 2002-03-13
JP2002518400A (ja) 2002-06-25
EP1087978A1 (fr) 2001-04-04
RU2229299C2 (ru) 2004-05-27
TW513434B (en) 2002-12-11

Similar Documents

Publication Publication Date Title
HUP0102300A2 (hu) Diazepinszármazékok alkalmazása szomatosztatin-receptor által befolyásolt betegségek kezelésére szánt gyógyszerek előállítására, valamint új vegyületek
HK1068334A1 (en) Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
HUP0105414A2 (hu) Pirrolo-izokinolin-, azepino- és diazepino-indol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
NO994452D0 (no) Substituerte 4-arylmetylen-2-imino-2,3-dihydrotiazoler og derivater, og deres farmasöytiske anvendelse
HUP9902459A2 (hu) Szubsztituált indazolszármazékok és felhasználásuk IV-típusú foszfodiészteráz (PDE) aktivitásának, és a tumornekrózis-faktor (TNF) keletkezésének gátlására
NZ520071A (en) 4-aminopiperidine derivatives and their use as medicine
HUP0500455A2 (hu) Parciális és teljes A1-agonisták N6-heterociklusos-5'-tiocsoporttal szubsztituált adenozinszármazékok
RU2006122853A (ru) Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
DE69530094D1 (de) Thiazolidindione derivate, ihre herstellung und verwendung
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
HUP9902148A2 (hu) Új 2,3-diszubsztituált-4(3H)-kinazolinonok
NO20033145D0 (no) Purinderivater som purinergiske reseptorantagonister
IL158343A (en) Dopamine glycoconjugate compounds, pharmaceutical compositions comprising them, processes for their preparation and use thereof in the manufacture of medicaments and as medicaments for treating parkinson's disease
HUP0202989A2 (hu) Új hidantoin-, tiohidantoin-, pirimidindion- és tioxopirimidinon-származékok, eljárás előállításukra és gyógyszerként való alkalmazásuk
DK0565377T3 (da) Terapeutiske midler til behandling af Parkinsons sygdom
ATE233754T1 (de) Diphenyl-piperidin derivate
NO20053805L (no) Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav
DE60144246D1 (de) Imidazolderivate, verfahren zu deren herstellung und deren verwendung
HUP0001245A1 (hu) Új eritromicinszármazékok, eljárás a vegyületek előállítására és gyógyszerként történő alkalmazásuk
MXPA04001201A (es) Derivados tetraciclicos de indol como ligandos del receptor de 5-ht.
MX9700305A (es) Nuevos derivados de deazapurina; una clase de ligandos especificos del crf1.
HUP0400744A2 (hu) Piridoindolon származékok felhasználása rákellenes gyógyszerek előállítására
MX9703671A (es) Compuesto de aminometil arilo y ligandos selectivos del subtipo de receptor de la dopamina.
DE69626624D1 (de) Medikamente gegen trhombocytopenie
DE69907448D1 (de) Pyrido[2,3-b]indolizinderivate und aza analoge: crf1 spezifische liganden

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished